Suchergebnisse - "rucaparib"

PubPharm (404)

101

Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4) : an international, open-label, randomised, phase 3 trial

enthalten in: The Lancet. Oncology | 2022

von Kristeleit, R. | Lisyanskaya, A. | Fedenko, A. | +22

CommentIn: Lancet Oncol. 2022 Apr;23(4):440-441. - PMID 35298905

102

Total Synthesis of Rucaparib

enthalten in: The Journal of organic chemistry | 2022

von Park, J. | Cheon, C.

103

A review on mechanisms of resistance to PARP inhibitors

enthalten in: Indian journal of cancer | 2022

von Desai, C. | Pathak, A. | Limaye, S. | +2

104

Incidence of grade 3-4 adverse events, dose reduction, and treatment discontinuation in castration-resistant prostate cancer patients receiving PARP inhibitors : a meta-analysis

enthalten in: Expert opinion on drug metabolism & toxicology | 2022

von Rizzo, A. | Mollica, V. | Merler, S. | +5

105

Evaluation of phototoxicity induced by the anticancer drug rucaparib

enthalten in: Scientific reports | 2022

von Mateos-Pujante, A. | Jiménez, M. | Andreu, I.

106

DNA Repair Enzyme Poly(ADP-Ribose) Polymerase 1/2 (PARP1/2)-Targeted Nuclear Imaging and Radiotherapy

enthalten in: Cancers | 2022

von Nguyen, N. | Pacelli, A. | Nader, M. | +1

107

Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer Part 2 : Medical Perspectives

enthalten in: Cancers | 2022

von Quesada, S. | Fabbro, M. | Solassol, J.

108

Phase Ib SEASTAR Study : Combining Rucaparib and Sacituzumab Govitecan in Patients With Cancer With or Without Mutations in Homologous Recombination Repair Genes

enthalten in: JCO precision oncology | 2022

von Yap, T. | Hamilton, E. | Bauer, T. | +8

109

Proteomic Analysis Reveals Low-Dose PARP Inhibitor-Induced Differential Protein Expression in BRCA1-Mutated High-Grade Serous Ovarian Cancer Cells

enthalten in: Journal of the American Society for Mass Spectrometry | 2022

von Perez, J. | Twigg, C. | Guan, W. | +1

110

Guidelines for Management of Treatment-Emergent Adverse Events During Rucaparib Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer

enthalten in: Cancer management and research | 2022

von Labadie, B. | Morris, D. | Bryce, A. | +5